SG11202003114UA - Transthyretin immunoglobulin fusions - Google Patents
Transthyretin immunoglobulin fusionsInfo
- Publication number
- SG11202003114UA SG11202003114UA SG11202003114UA SG11202003114UA SG11202003114UA SG 11202003114U A SG11202003114U A SG 11202003114UA SG 11202003114U A SG11202003114U A SG 11202003114UA SG 11202003114U A SG11202003114U A SG 11202003114UA SG 11202003114U A SG11202003114U A SG 11202003114UA
- Authority
- SG
- Singapore
- Prior art keywords
- transthyretin
- immunoglobulin fusions
- fusions
- immunoglobulin
- transthyretin immunoglobulin
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 108010071690 Prealbumin Proteins 0.000 title 1
- 102000009190 Transthyretin Human genes 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762568217P | 2017-10-04 | 2017-10-04 | |
PCT/US2018/054237 WO2019070901A1 (en) | 2017-10-04 | 2018-10-03 | Transthyretin immunoglobulin fusions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003114UA true SG11202003114UA (en) | 2020-05-28 |
Family
ID=64110020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003114UA SG11202003114UA (en) | 2017-10-04 | 2018-10-03 | Transthyretin immunoglobulin fusions |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200317795A1 (en) |
EP (1) | EP3692061A1 (en) |
JP (2) | JP2020537506A (en) |
KR (1) | KR20200059281A (en) |
CN (1) | CN111164101A (en) |
AU (1) | AU2018346151A1 (en) |
CA (1) | CA3076630A1 (en) |
EA (1) | EA202090581A1 (en) |
MA (1) | MA50619A (en) |
MX (1) | MX2020003549A (en) |
SG (1) | SG11202003114UA (en) |
WO (1) | WO2019070901A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114127125A (en) * | 2019-07-08 | 2022-03-01 | 安进公司 | Multispecific thyroxin transporter immunoglobulin fusions |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US233A (en) | 1837-06-14 | Improvement in plows | ||
US4447A (en) | 1846-04-04 | Car- wheel | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
EP0088046B1 (en) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipids in the aqueous phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
ES2776657T3 (en) | 2005-06-14 | 2020-07-31 | Amgen Inc | Self-buffering protein formulations |
GB0601513D0 (en) * | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
AU2010265933B2 (en) | 2009-06-26 | 2015-05-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
TWI636994B (en) * | 2010-10-27 | 2018-10-01 | 安美基公司 | Dkk1 antibodies and methods of use |
US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
JP5782185B2 (en) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | Packet transfer processing method and packet transfer processing device |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
AP2015008732A0 (en) * | 2013-03-15 | 2015-09-30 | Amgen Inc | Human pac1 antibodies |
CA2915386A1 (en) | 2013-06-26 | 2014-12-31 | Amgen Inc. | Cb1 receptor antigen-binding proteins and uses thereof |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
WO2017083604A1 (en) | 2015-11-12 | 2017-05-18 | Amgen Inc. | Triazine mediated pharmacokinetic enhancement of therapeutics |
CN106977609B (en) * | 2017-04-19 | 2020-07-28 | 刘崇东 | Fusion protein, preparation method and application thereof |
-
2018
- 2018-10-03 SG SG11202003114UA patent/SG11202003114UA/en unknown
- 2018-10-03 MA MA050619A patent/MA50619A/en unknown
- 2018-10-03 EA EA202090581A patent/EA202090581A1/en unknown
- 2018-10-03 AU AU2018346151A patent/AU2018346151A1/en active Pending
- 2018-10-03 CN CN201880063927.6A patent/CN111164101A/en active Pending
- 2018-10-03 CA CA3076630A patent/CA3076630A1/en active Pending
- 2018-10-03 EP EP18797214.6A patent/EP3692061A1/en active Pending
- 2018-10-03 JP JP2020516448A patent/JP2020537506A/en active Pending
- 2018-10-03 US US16/753,216 patent/US20200317795A1/en active Pending
- 2018-10-03 WO PCT/US2018/054237 patent/WO2019070901A1/en unknown
- 2018-10-03 MX MX2020003549A patent/MX2020003549A/en unknown
- 2018-10-03 KR KR1020207012219A patent/KR20200059281A/en not_active Application Discontinuation
-
2023
- 2023-10-18 JP JP2023179333A patent/JP2024012336A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024012336A (en) | 2024-01-30 |
CA3076630A1 (en) | 2019-04-11 |
MX2020003549A (en) | 2020-08-03 |
EA202090581A1 (en) | 2020-08-31 |
WO2019070901A1 (en) | 2019-04-11 |
MA50619A (en) | 2020-08-12 |
AU2018346151A1 (en) | 2020-04-02 |
JP2020537506A (en) | 2020-12-24 |
CN111164101A (en) | 2020-05-15 |
KR20200059281A (en) | 2020-05-28 |
EP3692061A1 (en) | 2020-08-12 |
US20200317795A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268517A (en) | Anti-tigit antibodies | |
ZA201905966B (en) | Anti-lag3 antibodies | |
IL272227A (en) | Anti-tigit antibodies | |
IL267797B1 (en) | Anti-gpc3 antibody | |
GB201709808D0 (en) | Antibodies | |
HUE046661T2 (en) | Sirp-alpha immunoglobulin fusion proteins | |
GB201721338D0 (en) | Anti-icos Antibodies | |
SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
IL266143A (en) | Antibody constructs | |
ZA202002141B (en) | Anti-transthyretin antibodies | |
IL262776A (en) | Humanized anti-il-1r3 antibodies | |
GB201720970D0 (en) | Antibodies | |
ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
IL273529A (en) | Anti-pacap antibody | |
IL271067A (en) | Anti-trkb antibodies | |
SG11202003114UA (en) | Transthyretin immunoglobulin fusions | |
SG11202112762TA (en) | Multispecific transthyretin immunoglobulin fusions | |
GB201711785D0 (en) | Antibodies | |
GB201717006D0 (en) | Anti-OPG antibodies | |
GB201709592D0 (en) | Antibody | |
GB201709818D0 (en) | Antibodies | |
GB201703071D0 (en) | Antibodies | |
GB201701416D0 (en) | Anti-OPG antibodies |